AWARD NUMBER: W81XWH-14-1-0115

TITLE: Cell of Origin and Cancer Stem Cell Phenotype in Medulloblastomas

PRINCIPAL INVESTIGATOR: Kyuson Yun, Ph.D.

CONTRACTING ORGANIZATION: The Jackson Laboratory

Bar Harbor, ME 04609

REPORT DATE: July 2016

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
July 2016	Annual	1 Jul 2015 - 30 Jun 2016
4. TITLE AND SUBTITLE		5a. CONTRACT NUMBER
Cell of Origin and Cancer	Stem Cell Phenotype in	
Medulloblastomas		5b. GRANT NUMBER
		W81XWH-14-1-0115
		5c. PROGRAM ELEMENT NUMBER
6. AUTHOR(S) Kyuson Yun, Ph.D.		5d. PROJECT NUMBER
nyabon rany rm.b.		5e. TASK NUMBER
		Se. TASK NUMBER
E-Mail: kyuson.yun@jax.org		5f. WORK UNIT NUMBER
- maii. It as off. I also jair. or g		
7. PERFORMING ORGANIZATION NAME(S	S) AND ADDRESS(ES)	8. PERFORMING ORGANIZATION REPORT NUMBER
The Jackson Laboratory		
600 Main Street		
Bar Harbor, ME 04609-1523		
9. SPONSORING / MONITORING AGENCY	NAME(S) AND ADDRESS(ES)	10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and M		
Fort Detrick, Maryland 21702-5012		11. SPONSOR/MONITOR'S REPORT
		NUMBER(S)
		l

12. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT The goal of this project is to test our hypothesis that cellular context in which initiating oncogenic event occurs may have a dominant role over specific oncogene function in determining the molecular phenotype of each tumor. To test this hypothesis, we proposed to transform neural stem cells (NSCs) and neural progenitor cells (NPCs) in vivo by expressing an activated form of Notch1 (N1ICD) or oncogenic PIK3CA (PIK3CAH1047R) in the developing mouse cerebellum, using cell type- specific Cre drivers (En2-Cre for NSCs and Atoh1-creER for NPCs). In the last year, we aged >10 N1ICD; En2-Cre; p53-/- mice and observed that while some of these mice became sick, none of them developed frank tumors, suggesting that En2+ population cannot be transformed by N1ICD expression. Therefore, we discontinued this mating and changed the Cre driver in NSCs to hGFAP-cre and Sox2-CreER. We are now aging N1ICD; SOX2-CreER; p53-/- and N1ICD; hGFAP-cre; p53-/- mice to collect tumors. In addition, we successfully intercrossed PIK3CAH1047R (a frequent mutant allele of PIK3CA observed in human cancer) to Sox2CreER, Atoh1-creER, and p53-/- strains to generate PIK3CAH1047R;Sox2-creER;p53-/- and PIK3CAH1047R; Atoh1-CreER; p53-/- mice. We are currently aging these mice for them to form medulloblastomas. Also as a backup, we started generating a YAP-induced medulloblastoma We anticipate collecting samples from either the PIK3CAH1047R- or YAP-induced models in the next year to complete this study.

15. SUBJECT TERMS cancer stem cells, medulloblastoma, targeted therapy, therapy resistance, pediatric cancer, brain tumor, Notchl, PIK3CA, cell of origin, molecular subtypes, neural stem cells, neural progenitor cells, tumor initiation.

16. SECURITY CLAS	SIFICATION OF:		17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT	b. ABSTRACT	c. THIS PAGE	UU	12	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	Page
1 Tutus Justina	4
1. Introduction	
3. Accomplishments	
4. Impact	7
5. Changes/Problems	7
6. Products	7
7. Participants & Other Collaborating Organizations	8
8. Special Reporting Requirements	12
9 Annendices	12

DoD Award W81XWH-14-1-0115 - Progress Report

1. INTRODUCTION:

The goal of this project is to test our **hypothesis that cells in various stages of maturation in the developing brain produce tumors with distinct biological characteristics when transformed by the same oncogenic event.** This hypothesis was based on our observations that certain oncogenes, such as *Id2* and constitutively active *Notch1* (N1ICD), induced DNA damage and apoptosis when activated in neural stem cells (NSCs) *in vivo* but had no observable effect when activated in neural progenitor cells (NPCs), immediate progenies of NSCs. These observations indicate that epigenetic changes that occur during NSC-NPC transition somehow block oncogenes from functioning in NPCs. In other words, cellular context in which tumors initiate may have a dominant role over some oncogene function.

In addition, we recently reported that cancer stem cells (CSCs)- stem cell like cells in tumors that have stem cell properties and tumor initiating ability- retain epigenetic memories of their cells of origin (Chow et al., 2014). We showed that CSCs derived from NSCs and NPCs depend on different mitogenic and survival pathways, even when they are transformed by the same oncogene *in vivo*. This finding has multiple implications: one of the most significant being that targeted therapies selected based on bulk tumor cell analysis may be ineffective in eradicating CSCs. We showed in a SHH medulloblastoma model that responsiveness of CSCs to SHH inhibitors therapies varied greatly depending on the cell type in which tumor initiation occurred *in vivo*. If this novel discovery were generalizable, it would suggest that we will need to analyze CSCs (rare cells in the tumor) and not just the bulk tumor cells (current practice) to identify therapy combinations that will eradicate both CSCs and non-stem (bulk) tumor cells.

To directly test whether the cell-of-origin or the activated oncogene itself has more dominant role in determining molecular phenotypes of bulk tumor cells and CSCs, we proposed to generate and analyze spontaneous medulloblastomas by transforming NSCs and NPCs by expression of an activated form of *Notch1* (N1ICD) or oncogenic *PIK3CA* in the developing mouse cerebellum, using cell type- specific Cre drivers (*En2-Cre for NSCs and Atoh1-creER for NPCs*).

2. KEYWORDS:

cancer stem cells, medulloblastoma, targeted therapy, therapy resistance, pediatric cancer, brain tumor, Notch1, PIK3CA, cell of origin, molecular subtypes, neural stem cells, neural progenitor cells, tumor initiation.

3. ACCOMPLISHMENTS:

Major goals of the project:

The stated goals of this project are to: 1) test the general applicability of our observation across multiple tumor models in which different oncogenic events initiate tumor formation and 2) test our hypothesis that cells in different stages of maturation in developing organs produce tumors with distinct molecular and cellular characteristics even when the initiating oncogenic event is the same.

To test the general applicability of our novel hypothesis, we will transform NSCs and NPCs in the developing mouse cerebellum using cell stage- specific Cre drivers (*En2-Cre or GFAP-cre for NSCs* and *Atoh1-creER or Olig2-cre for NPCs*). We will express activated *Notch1* (N1ICD) or an oncogenic mutant form of PIK3CA in *p53-/-* brains. We will analyze both bulk tumor cells and CSCs from each of these models and compare their molecular and cellular characteristics, including CSC culture behavior and AKT activation. We will also compare molecular profiles of bulk tumors and CSCs of these tumors to determine whether the oncogene or the cellular context plays a more dominant role in driving the molecular phenotypes by unsupervised clustering analyses.

What was accomplished:

During this period, we focused on generating new models of medulloblastoma by activating N1ICD and PIK3CA in cerebellar NSCs and NPCs in the developing mouse brain.

N1ICD models:

We previously published that activated Notch1 (N1ICD) expression in the developing brain induces apoptosis due to DNA damage and p53 activation. When p53 is genetically deleted, ~40% of N1ICD;GFAP-cre;p53-/- mice developed spontaneous medulloblastomas (Natarajan et al., 2013). To generate medulloblastomas that arise from transformed NSCs, we intercrossed N1ICD, En2-Cre, and p53 strains to generate N1ICD;En2-cre;p53-/- mice. To date, we have generated more than eight N1ICD;En2-cre;p53-/- mice; however, none of them formed medulloblastomas. The triple transgenic mice are viable, although they have shorter life span than wildtype mice. They appear to succumb to neurological defects.

To activate the same transgene in NPCs in the external granule layer (EGL), we intercrossed *N1ICD*, *Atoh1-CreER*, and *p53* strains to generate *N1ICD;Atoh1-CreER;p53-/-*. We activated the transgene in these mice by treating p3-5 pups with Tamoxifen. Thus far, we have not observed any medulloblastomas from these mice. We are currently aging these mice to collect medulloblastoma samples for analysis.

PIK3CA models:

Because the reviewers had asked for (and DoD approved) switching out *Xrcc2-/-*induced medulloblastoma model (proposed in the original submission) with PIK3CAinduced medulloblastoma model, we are behind schedule in terms of generating tumors. We first analyzed the effects of PIK3CA* expression in different cellular compartments in the developing brain. As shown in Figure 1, expression of mutant PIK3CA* in the developing embryo brain (by Nestin-Cre) induced severe dysplasia (Fig 1A, B), and PIK3CA*;Nestincre mice died with hydrocephalus by weaning age. We validated elevated PIK3CA signaling in these brains by increased pAKT and pS6 expression in transgenic brains (Fig. 1C, D). PIK3CA* expression in slightly more mature neuroepithelium (by GFAP-Cre) induced milder dysplasia with prominent rosette formation in the neuroepithelium in PIK3CA*;hGFAP-cre brains (Fig 1E), but still resulted in hydrocephalus and lethality by weaning age. Interestingly,




Figure 1. Postnatal day 5 PIK3CA*;Nestin-cre and control brains stained with (A) H&E, (B) NeuN, a neuronal marker, (C) pAKT, and (D) pS6. (E) E15.5 PIK3CA*;GFAP-Cre brain stained with H&E showing rosettes in neuroepithelium. Gross (F) and H&E (G) stained images of control (left) and PIK3CA*;Ngn1-cre brain (right) at 2 months showing megacephaly. Abb: ctx=cortex, cb=cerebellum, hp= hippocampus

PIK3CA* expression in committed neural progenitors (by Ngn1-cre) did not result in dysplasia although the *PIK3CA*;Ngn1-cre* brains are megacephalic, Fig 1F, G). These mice also died around 2 months of age of unknown reasons. These analyses showed that the PIK3CA* transgenic model we use is functional and that oncogenic PIK3CA expression in the developing brain affects proliferation and differentiation, as anticipated.

To circumvent early lethality associated with PIK3CA* expression, we made two modifications to our approach. First, we used a different and more clinically-relevant allele of PIK3CA, *PIK3CAH1047R*, to activate the PI3K pathway. Unfortunately,

PIK3CAH1047R; Nestin-cre mice die soon after birth. They are born with obvious megacephaly (not shown). To circumvent this early developmental defect, we switched our Cre driver to Sox2-CreER. In these mice, Cre is activated in Sox2+ cells only when treated with Tamoxifen. We generated **PIK3CAH1047R; Sox2CreER** mice and treated them with Tamoxifen at p3-p5. We are aging these mice to test whether they develop spontaneous tumors.


To generate new medulloblastoma models induced by PIK3CA* expression, we directed PIK3CA* expression in the developing cerebellum by mating PIK3CA* mice to the En2-Cre driver. En2-Cre is active in mid/hind brain neuroepithelium from very early on (E9.0 onwards). *PIK3CA*;En2-cre* mice are viable (>240 days) but they have hypoplastic vermis and hyperplastic superior collilus (Fig 2A), suggesting that the effects of PIK3CA* expression is cell context-specific. Furthermore, cerebellar hemispheres were disorganized (Fig. 2B), and marker analyses for activated PI3K pathway (pS6, Fig. 2C), purkinje neurons (calbindin, Fig 2D), and proliferation (Ki67, Fig 2E) suggest that aberrant elevation of PIK3CA signaling affects cell proliferation/survival, differentiation and migration. Together, these results indicate that PIK3CA* expression in early cerebellar stem cells may result in oncogene-induced apoptosis or senescence at an early age. To test whether PIK3CA* expression induced p-53 dependent apoptosis and whether blocking this process induces tumor formation, we generated PIK3CA*;En2-cre;p53-/-. Again, these mice are viable and no tumor formation has been observed vet.

We are currently analyzing PIK3CAH1047R* expression in cerebellar NPCs, using *Atoh1-CreER* inducible driver in EGL progenitor cells. We will determine whether embryonic and

postnatal day EGL progenitor cells respond similarly as NCSs to PIK3CAH1047R* expression and whether deleting the p53 tumor suppressor gene function will result in spontaneous medulloblastoma formation.

Alternative models of medulloblastoma:

Despite our Continued efforts to produce PIK3CA-* induced medulloblastomas, so far, we have not observed any localized tumors in the cerebellum. Since PIK3CA* is a strong allele of PIK3CA (truncation mutation), we tested a common point mutation in PIK3CA gene in human tumors, PIK3CA H1047R. We are currently crossing this strain to various Cre drivers described above.






Figure 2. Littermate control and PIK3CA*'En2-cre;p53+/- brains at 6 months (A) gross images, (B) H&E, (C) pS6, (D) calbindin, and (E) Kl67 staining. Arrows in A point to inferior colliculus, arrowheads point to vermis.




Figure 3. YapS5A;AtohCreER medulloblastoma, stained with H&E or antibodies against YAP, cleaved Caspase 3, and Ki67 as indicated.

In parallel, we are developing a new medulloblastoma model induced by expression of constitutively active YAP. YAP is a transcriptional effector of the Hippo pathway and its expression is elevated in SHH subgroup of human medulloblastomas. Interestingly, it is amplified in a subset of SHH medulloblastomas, suggesting that it may be an oncogene. To test this directly, we expressed YapS5A (constitutively active form of YAP) in the developing cerebellum by treating **YapS5A;AtohCreER** mice with Tamoxifen at p3-p5. One of the three **YapS5A;AtohCreER** mice developed a spontaneous medulloblastoma (Fig. 3). We propose to study YapS5A-induced tumors if we cannot generate PIK3CA-induced medulloblastomas.

Training opportunities: N/A

Results dissemination: Nothing to report

Plan for the no-cost extension period:

We will continue to intercross and generate triple transgenic mice and age them to collect at least 10 tumors of each genotype (N1ICD;Atoh1-CreER;p53, N1ICD;Sox2-Cre;p53, PIK3CAH1047R;Atoh1-CreER;p53, and PIK3CAH1047R;Sox2-Cre;p53). If we do not observe significant tumor incidences in PIK3CA-induced models in the next 6 months, we will replace those with YapS5A induced models. We will analyze their transcriptomes to determine whether the cell of origin or the oncogene function plays a dominant role in determining the molecular phenotypes of medulloblastomas.

4. IMPACT:

Impact of the principal and other disciplines: Nothing to report

Impact on technology transfer: Nothing to report

Impact on Society: Nothing to report

5. CHANGES/PROBLEMS:

Problems or delays:

This project is a little delayed due to two main reasons. One, we observed higher than anticipated incidence of sarcoma formation from mice in p53+/- or p53-/- backgrounds. We had to sacrifice triple transgenic mice before they could form brain tumors; hence, we are behind schedule in terms of collecting spontaneous medulloblastomas. To bypass this limitation, we started crossing floxed-p53 mice to N1ICD and PIK3CA* mice so that we can delete p53 only in cells that are also expressing N1ICD or PPIK3CA* oncogenes in the brain. The second reason for the delay is that the reviewers had asked us to change the second oncogenic event (*Xrcc2* deletion) to a more clinically–relevant genetic event (we chose PIK3CA mutation). This change was approved pre-award by DoD. However, since this is a new model, we had to do more model characterization than anticipated, which caused some delay. We continue to mate these mice to generate transgenic mice; however, if the tumor incidence rate is low or the latency is too long, we will switch the model to YapS5A induced models.

Changes with significant impact on expenditure: Nothing to report

Changes to human subjects, animals, or agents: Nothing to report

6. PRODUCTS: Nothing to report

7. PARTICIPATION & OTHER COLLABORATING ORGANIZATIONS:

What individuals have worked on the project?

Name	Kyuson Yun
Project Role	Principal Investigator
Researcher Identifier (NIH Commons ID)	KYUSONYUN
Nearest person month worked	6
Contribution to Project	overall supervision, experimental design and analysis.
Funding Support	N/A
Name	Kin-Hoe Chow
Project Role	Postdoctoral Associate
Researcher Identifier (NIH Commons ID)	KINHOECHOW
Nearest person month worked	2
Contribution to Project	generation and analysis of new medulloblastoma models
Funding Support	N/A
Name	Keiko Yamamoto
Project Role	Research Assistant
Researcher Identifier	N/A
Nearest person month worked	2
Contribution to Project	animal husbandry to generate new models of medulloblastoma
Funding Support	N/A
Name	Rachael McMinimy
Project Role	Co-Op Associate
Researcher Identifier	N/A
Nearest person month worked	2
Contribution to Project	histological analysis of new medulloblastoma models
Funding Support	N/A
	,
Name	Ryota Nakada
Project Role	Co-Op Associate
Researcher Identifier	N/A
Nearest person month worked	1
Contribution to Project	PCR genotyping to set up appropriate mating and histological analysis of mutant brains.
Funding Support	N/A

Has there been a change in the active other support of the PD/PIs or senior/key personnel since the last reporting period?

Yes. Dr. Yun's current other support is detailed below (changes are indicated in italics.)

Yun, Kyuson

<u>Active</u>

Supporting Agency:	NIH/NCI 5 R21 CA191848-02	PI:	Chuang	
Project Title:	Dissection of Tumor Evolution Using Pat	section of Tumor Evolution Using Patient-Derived Xenografts		
Role:	Co-Investigator	Effort:	0.60 CM	
Entire Project:	07/01/2015 - 06/30/2017	\$531,39	99	
Current Year:	07/01/2016 - 06/30/2017	\$204,10	00	
Project Goals:	The goal of this exploratory study is to test and apply patient-derived xenografts (PDX) as an improved system to quantify rates of tumor subclonal population evolution.			
Specific Aims:	1: Spatial and Temporal Dissection of Subclonal Heterogeneity in Breast Cancer Xenografts - a. Characterization of spatially and temporally separated breast cancer xenografts; b. Computational identification and analysis of subpopulations; c. Validation of subpopulations by single-cell sequencing; 2: Determination of Subclonal Evolution During Drug Treatment - a. Genomic and histological characterization of spatially and temporally separated xenografts under drug treatment; b. Identification, analysis, and validation of subpopulations relevant to therapy response.			
Overlap:	None			
Contracting/ Grants Officer:	Sarah M. Lee - <u>sarah.lee@nih.gov</u>			

	Donaldson Charitable Trust DONALDSON-FY15-KY-01	PI:	Yun	
Project Title:	Understanding the earliest steps in c	Understanding the earliest steps in cancer formation		
Role:	Principal Investigator	Effort:	3.60 CM	
Entire Project:	12/07/2015 - 12/06/2016	\$133,8	275	
Current Year:	12/07/2015 - 12/06/2016	\$133,8	275	
Project Goals:		The goal of this project is to test they hypothesis that different epigeitic ststates of the stem and progenitor cells either allow or suppress oncogenes to initiate tumors in vivo.		
Specific Aims:	Map and compare open chromatin regions in neural stem cells and neural progenitor cells from the developoing mouse brain to eludicate differential vulnerabilities of these two populations to oncogene induced DNA damage and transformation			
Overlap:	None			
Contracting/ Grants Officer:	Allen Mast, Corporate Trustee			

Supporting Agency:	The Jackson Laboratory Director's	PI:	Choi, Yun	
	Innovation Fund JAX-BIDMC-Pilot-FY15-			
	Choi-Yun			
Project Title:	Development of Brain Tumor-Targeted Th	eragnosti	c Agents for Clinical	
	Translation			
Role:	Principal Investigator	Effort:	0.60 CM	
Entire Project:	09/01/2015 - 08/31/2016	\$45,000		
Current Year:	09/01/2015 - 08/31/2016	\$45,000		
Project Goals:	The goal of this project is to develop a bifu			
	surgeons with real-time image guidance d	uring brai	n tumor surgery and induce	
	cancer cell death in distantly infiltrated tun	cancer cell death in distantly infiltrated tumor cells that cannot be resected.		
Specific Aims:	1. Validate general applicability and clinical potential of SP66 as a theragnostic			
-	agent by measuring tumor uptake in PDX GBM models and a spontaneous			
	mouse medulloblastoma model; 2. Evalua	te the the	rapeutic potential of SP66 in	
	vitro and in vivo.			
Overlap:	None			
Contracting/	Rita Poirier - rita.poirier@jax.org			
Grants Officer:				

Supporting Agency:	Maine Medical Center NSI-1101-001 2015	PI:	Emery	
Project Title:	Inhibition of Stem Cell Pathways in a Patient-Derived GMB Tumor Model System			
Role:	Consortium PI	Effort:	0.12 CM	
Entire Project:	10/01/2015 - 09/30/2016	\$15,000)	
Current Year:	10/01/2015 - 09/30/2016	\$15,000)	
Project Goals:	The goal of this study is to elucidate the	role of ABC	CG2 in glioma stem cells.	
Specific Aims:	evaluate the therapeutic potential of ABCG2 inhibitors on primary GBM tumorspheres			
Overlap:	None			
Contracting/ Grants Officer:	Michele Locker - lockem@mmc.org			
Supporting Agency:	St. Baldrick's Foundation	PI:	Yun	
Project Title:	Preclinical Evaluation of Treating SHH M	ledulloblas	tomas with Yap1 Inhibitors	
Role:	Principal Investigator	Effort:	0.12 CM	
Entire Project:	06/12/2016 - 08/12/2016	\$5,000	•	
Current Year:	06/12/2016 - 08/12/2016	\$5,000		
Project Goals:	These funds are to support a summer fellowship position in Dr. Yun's laboratory.			
Specific Aims:	N/A			
Overlap:	None			
Contracting/ Grants Officer:	Liz Jackson - <u>liz@stbaldricks.org</u>			

Submitted

Supporting Agency:	NIH/NCI 1 R01 CA195700-01A1	PI:	Yun
Project Title:	Validation and Generation of Matching GBM PDX and Tumorsphere Cultures		
	as Translational Research Tools		
Role:	Principal Investigator	Effort:	4.00 CM
Entire Project:	09/01/2016 - 08/31/2019	\$2,404,2	222
Current Year:	09/01/2016 - 08/31/2017	\$796,19	9
Project Goals:	Our goals of this project are to elucidate inherent biases in patient-derived xenograft (PDX) and tumorsphere models to enable more comprehensive modeling of Glioblastoma multiforme (GBM) in the future, and to validate our optimized ex vivo tumor slice system using PDX models as a clinically relevant tool for translational research.		
Specific Aims:	1. Elucidate selective bias in establishing and propagating PDX models of human GBMs; 2. Determine the heterogeneity of tumor- initiating and sphere-forming cells in human GBMs; 3. Validate ex vivo tumor slice cultures from GBM PDX models as a platform for translational research.		
Overlap:	None		
Contracting/ Grants Officer:	Mariam Eljanne - eljannem@mail.nih.gov		

Completed

Supporting Agency:	Maine Technology Institute SG5424	PI:	Yun
Project Title:	Development of Novel Anti-cancer Agents		
Role:	Principal Investigator	Effort:	0.12 CM
Entire Project:	07/01/2015 - 06/30/2016	\$25,000	

Supporting Agency:	American Brain Tumor Association	PI:	Yun, Kyuson
Project Title:	Predicting Therapy Resistance Based on (Cancer St	em Cell Phenotypes
Role:	Principal Investigator	Effort:	0.60 CM
Entire Project:	07/01/2013 - 06/30/2014	\$50,000	

Supporting Agency:	Maine Cancer Foundation	PI:	Yun, Kyuson
Project Title:	Development of Ex Vivo Organotypic Slice	Culture S	Systems for Cancer Studies
Role:	Principal Investigator	Effort:	1.20 CM
Entire Project:	07/01/2013 - 06/30/2015	\$164,68	6

Supporting Agency:	The Jackson Laboratory Director's Innovation Fund	PI:	Yun, Kyuson
Project Title:	Postdoctoral Associate Support	•	
Role:	Principal Investigator	Effort:	0.12 CM
Entire Project:	08/01/2013 - 07/31/2014	\$160,00	00

Supporting Agency:	American Cancer Society	PI:	Yun, Kyuson
	118571-RSG-10-042-01-DDC		•
Project Title:	S100a4 Expression and Function in Brain Cancer Stem Cells		
Role:	Principal Investigator	Effort:	2.40 CM
Entire Project:	01/01/2010 - 12/31/2014	\$720,00	0

Supporting Agency:	Oliver S. and Jennie R. Donaldson	PI:	Yun, Kyuson
	Charitable Trust		-
Project Title:	Cancer Risk Factors and Cell Type: Elucidating Brain Cancer Formation		
Role:	Principal Investigator	Effort:	1.20 CM
Entire Project:	12/17/2013 - 12/16/2015	\$325,00	0

What other organizations were involved as partners?

Nothing to report

8. SPECIAL REPORTING REQUIREMENTS: none

9. APPENDICES: N/A